Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37.5--50% having been found. Treatment with aminoglutethimide of only four premenopausal breast cancer patients has been reported in which two patients responded. The clinical and endocrine effects of 1000 mg aminoglutethimide daily and 20 mg hydrocortisone twice daily were studied in 18 premenopausal patients with breast cancer. Eight patients developed menstrual abnormalities, but there were no objective tumor responses in the 14 patients with assessable disease. Adrenal suppression was produced in all patients, with dehydroepiandrosterone sulfate levels suppressed to 20% of baseline values. Estrone and estradiol levels were not suppressed into the postmenopausal range. However, the therapeutic regime resulted in suppression of estrogen peaks after Pergonal administration, thus demonstrating a partial block of ovarian estrogen synthesis.

Original publication

DOI

10.1210/jcem-55-4-718

Type

Journal article

Journal

J Clin Endocrinol Metab

Publication Date

10/1982

Volume

55

Pages

718 - 722

Keywords

Adult, Aminoglutethimide, Androstenedione, Breast Neoplasms, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Drug Therapy, Combination, Estradiol, Female, Humans, Hydrocortisone, Hydroxyprogesterones, Menopause, Menstruation, Middle Aged